Prophylactic Ketorolac Post Epiretinal Membrane Surgery
NCT ID: NCT00974753
Last Updated: 2016-01-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
18 participants
INTERVENTIONAL
2010-03-31
2012-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prophylactic Nepafenac and Ketorolac Versus Placebo in Patients Undergoing Cataract Surgery
NCT01395069
Effect of Prophylactic Ketorolac on CME After Cataract Surgery
NCT00335439
Anti-inflammatory Efficacy for Prophylaxis of Cystoid Macular Edema (CME) After Phacoemulsification
NCT02084576
Anti-inflammatory Therapy Following Selective Laser Trabeculoplasty
NCT00485108
A Comparison of Post Phacoemulsification Aqueous Flare in Patients Using Ketorolac 0.45% 2 Times Daily (BID) and Bromfenac 0.09% 2 Times Daily (BID)
NCT01023724
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PPV-MP + Placebo (Saline drops)
PPV-MP= pars plana vitrectomy membrane peel
Saline drops
Four-times a day starting one week before surgery and continued for 4 weeks post surgery.
PPV-MP + Ketorolac 0.5%
PPV-MP= pars plana vitrectomy membrane peel
Ketorolac 0.5%
Four-times a day starting one week before surgery and continued for 4 weeks post surgery.
PhacoVit-MP + Placebo (Saline drops)
PhacoVit-MP= phacovitrectomy membrane peel
Saline drops
Four-times a day starting one week before surgery and continued for 4 weeks post surgery.
PhacoVit-MP + Ketorolac 0.5%.
PhacoVit-MP= phacovitrectomy membrane peel
Ketorolac 0.5%
Four-times a day starting one week before surgery and continued for 4 weeks post surgery.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ketorolac 0.5%
Four-times a day starting one week before surgery and continued for 4 weeks post surgery.
Saline drops
Four-times a day starting one week before surgery and continued for 4 weeks post surgery.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* sickle cell retinopathy
* radiation retinopathy
* choroidal folds
* hypersensitivity or allergy to NSAIDs
* wet macular degeneration
* branch retinal vein occlusion (BRVO)
* central retinal vein occlusion (CRVO)
* complicated membrane peel surgery
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Queen's University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jeff Gale, MD, FRCSC
Role: PRINCIPAL_INVESTIGATOR
Queen's University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Ophthalmology, Hotel Dieu Hospital, Queen's University
Kingston, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ERM-JG-2009
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.